Business Description
Tevogen Bio Holdings Inc
NAICS : 541714
SIC : 8731
ISIN : US88165K1016
Total Employee Number:
18Description
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.07 | |||||
Equity-to-Asset | -2 | |||||
Debt-to-Equity | -0.96 | |||||
Debt-to-EBITDA | -0.46 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year FCF Growth Rate | -134.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 25.25 | |||||
14-Day RSI | 29.72 | |||||
6-1 Month Momentum % | -42.54 | |||||
12-1 Month Momentum % | -84.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.29 | |||||
Quick Ratio | 0.29 | |||||
Cash Ratio | 0.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.3 | |||||
Shareholder Yield % | -29.64 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -482.27 | |||||
ROIC % | -478.37 | |||||
3-Year ROIIC % | 7.16 | |||||
ROC (Joel Greenblatt) % | -1549.44 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -1.75 | |||||
EV-to-Forward-EBIT | -5.61 | |||||
EV-to-EBITDA | -1.79 | |||||
EV-to-FCF | -3.14 | |||||
Earnings Yield (Greenblatt) % | -57.14 | |||||
FCF Yield % | -60.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tevogen Bio Holdings Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -5.747 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 38.7 | ||
| 14-Day RSI | 29.72 | ||
| 14-Day ATR (€) | 0.000858 | ||
| 20-Day SMA (€) | 7.7 | ||
| 12-1 Month Momentum % | -84.98 | ||
| 52-Week Range (€) | 7.6 - 51.75 | ||
| Shares Outstanding (Mil) | 4.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tevogen Bio Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tevogen Bio Holdings Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 120 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 29 days | ||
| General meeting for 2025 | 2026-08-04 11:00 | In 20 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 7.70 (+0.00%) | ||
| Annual report for 2025 | 2026-03-31 | 7.70 (+0.00%) | ||
| 0.02:1 Stock Split | 2026-03-06 | 7.70 (+0.98%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 19.70 (+3.41%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 40.50 (+3.58%) | ||
| General meeting for 2024 | 2025-06-23 11:00 | 52.00 (+5.69%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 51.00 (+0.49%) |
Show
Entries
Tevogen Bio Holdings Inc Frequently Asked Questions
What is Tevogen Bio Holdings Inc(FRA:G280)'s stock price today?
The current price of FRA:G280 is €7.70. The 52 week high of FRA:G280 is €51.75 and 52 week low is €7.60.
When is next earnings date of Tevogen Bio Holdings Inc(FRA:G280)?
The next earnings date of Tevogen Bio Holdings Inc(FRA:G280) is 2026-08-14 Est..
Does Tevogen Bio Holdings Inc(FRA:G280) pay dividends? If so, how much?
Tevogen Bio Holdings Inc(FRA:G280) does not pay dividend.
Press Release
Articles on Tevogen Bio Holdings Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers